Should You Buy Tilray Stock Under $5?

Tilray reported fiscal 2026 revenue of $915.5 million, up 11% year over year, and adjusted EBITDA of $61.1 million, up 11.1%, but its shares have fallen nearly 56% year to date and more than 96.7% over five years on a split-adjusted basis. The central concern is continuing dilution: shares outstanding rose from 116.5 million on Jan. 6 to 136.2 million on July 26, while recreational cannabis contributes less than one-third of revenue and U.S. market exposure remains limited. Management targets $1 billion in revenue this fiscal year and has $235 million in cash with minimal debt, but the article expects losses, dilution, and lack of GAAP profitability to continue pressuring the stock.

Analysis

TLRY's core issue is not simply weak cannabis exposure; it is a financing-model mismatch. Low-margin distribution, beverage, and wellness revenue can support reported sales growth but does not establish the per-share cash generation needed to offset repeated equity issuance. Until management demonstrates durable positive operating cash flow after interest, capex, and working-capital needs, each growth target risks being valued as a future dilution event rather than a multiple-expansion catalyst.

The Carlsberg licensing arrangement is strategically useful but unlikely to alter the equity case in the next 1-3 months: branded-beverage launch costs, distributor economics, and shelf-placement payments may precede meaningful contribution. CARL.B has negligible direct earnings sensitivity; the more relevant read-through is whether Tilray can obtain mainstream U.S. distribution without consuming incremental capital. A failed or delayed rollout would reinforce that diversification is adding revenue complexity rather than high-return growth.

Consensus bearishness is directionally justified, but a crowded short in a low-priced, retail-owned name carries episodic squeeze risk around U.S. federal cannabis reform headlines. The structural thesis is falsified by two consecutive quarters of positive free cash flow, stable or declining diluted share count, and evidence that EBITDA converts to cash; absent those conditions, a 6-18 month valuation reset remains more probable than a sustained recovery.

Key Decisions for Investors

• Maintain an underweight/short bias in TLRY only on failed rallies following earnings or federal-reform headlines; use a 1-3 month horizon and size modestly given retail squeeze risk. Cover if diluted shares stabilize for two reporting periods and free cash flow turns sustainably positive.
• Prefer a pair trade short TLRY / long CARL.B only if the beer-license launch becomes a meaningful source of promotional optimism: CARL.B offers defensiveness and limited exposure to Tilray's funding risk, while TLRY remains exposed to execution and dilution. Reassess if launch disclosures show unexpectedly high-margin, minimum-guarantee economics for TLRY.
• Do not treat revenue or adjusted-EBITDA guidance as a catalyst without cash-flow detail. Set an alert for quarterly operating cash flow, capex, working-capital movement, and weighted-average diluted shares; a guidance raise unsupported by these metrics is a potential short-entry signal rather than confirmation of a turnaround.
• Avoid extrapolating a TLRY move into NFLX, NVDA, or GETY; they are incidental mentions with no fundamental linkage. CARL.B is the only listed ticker with a plausible, though immaterial, read-through.